BioAge Labs (BIOA) EBT (2023 - 2026)

BioAge Labs has disclosed EBT across 4 years of filings, most recently posting -$22.1 million for Q1 2026.

• EBT for Q1 2026 came in at -$22.1 million, down 70.52% year-over-year; the trailing twelve-month figure through Mar 2026 was -$89.6 million (down 25.8% YoY), and the FY2025 annual result was -$80.4 million, down 13.34% from the prior year.
• EBT came in at -$22.1 million for Q1 2026 at BioAge Labs, up from -$25.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$11.8 million in Q3 2023 to a low of -$25.7 million in Q4 2025.
• The 4-year median for EBT is -$20.1 million (2025), against an average of -$18.3 million.
• Across the five-year window, EBT plunged 95.92% in 2024 and advanced 12.87% in 2025, its largest moves.
• BioAge Labs' EBT stood at -$15.8 million in 2023, then sank by 36.83% to -$21.6 million in 2024, then decreased by 19.17% to -$25.7 million in 2025, then rose by 13.91% to -$22.1 million in 2026.
• The last three EBT figures came in at -$22.1 million (Q1 2026), -$25.7 million (Q4 2025), and -$20.1 million (Q3 2025), per Business Quant data.